![Jeff Knight](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jeff Knight
Directeur des opérations chez
ALX ONCOLOGY HOLDINGS INC.
Fortune : 716 830 $ au 31/05/2026
Profil
Jeff E Knight is Chief Operating & Development Officer at ALX Oncology Holdings, Inc. since 2026.
Former roles include Chief Development & Operating Officer at Crinetics Pharmaceuticals, Inc. from 2021 to 2026; SVP-Portfolio Management & Corporate Operations at Poseida Therapeutics, Inc. from 2018 to 2021; VP-Development Operations & Portfolio Management at Halozyme Therapeutics, Inc. from 2017 to 2018; Executive Director-Global Development Operations at Amgen, Inc. from 2015 to 2017; and VP-Clinical Operations & Project Management at Onyx Pharmaceuticals, Inc. from 2012 to 2018.
Education includes undergraduate studies at the University of Kansas and graduate studies at the University of Oklahoma.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/04/2026 | 20 164 ( 0,02% ) | 716 830 $ | 31/05/2026 |
Postes actifs de Jeff Knight
| Sociétés | Poste | Début |
|---|---|---|
| ALX ONCOLOGY HOLDINGS INC. | Directeur des opérations | 13/04/2026 |
Anciens postes connus de Jeff Knight
| Sociétés | Poste | Fin |
|---|---|---|
| CRINETICS PHARMACEUTICALS, INC. | Directeur des opérations | 10/04/2026 |
| POSEIDA THERAPEUTICS, INC. | Corporate Officer/Principal | 31/08/2021 |
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01/10/2018 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01/01/2018 |
| AMGEN INC. | Corporate Officer/Principal | 01/03/2017 |
Formation de Jeff Knight
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
48
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Halozyme Therapeutics, Inc.
 Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
University of Kansas
 University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oklahoma
 University of Oklahoma Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Crinetics Pharmaceuticals, Inc.
 Crinetics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets therapeutics for endocrine-related diseases | Health Technology |
Poseida Therapeutics, Inc.
 Poseida Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops next generation cell and gene therapeutics | Health Technology |
ALX Oncology Holdings, Inc.
 ALX Oncology Holdings, Inc. BiotechnologyHealth Technology Operates as clinical stage immuno-oncology company, which develops therapies for cancer | Health Technology |
